Skip to content

Maraviroc gets scientific thumbs up from European drugs body

Pfizer advises maraviroc dose increase if combined with etravirine

Darunavir superior to lopinavir in 48-week study in treatment-experienced patients

TMC-125 and darunavir show strong effect in highly treatment-experienced, even without T-20

Brazil: Kaletra price cut agreed as generic efavirenz arrives

Merck hopes for US integrase inhibitor license by October

Oral solution of bevirimat provides encouraging results, maturation inhibitor moves ahead

Maraviroc approval delayed in the US

Treating PML: hopes for future focus on mastering immune response